Novo Nordisk Reports New CagriSema Weight-Loss and Function Findings

Novo Nordisk announced two additional analyses of its late-stage REDEFINE 1 trial.

The analyses found differing weight-loss patterns among adults receiving CagriSema, the company’s experimental obesity treatment.

A separate analysis found improvements in daily functioning among adults receiving CagriSema.

CagriSema combines semaglutide, the active ingredient in Wegovy and Ozempic, with cagrilintide, which acts on a pathway involved in hunger and fullness. The late-stage REDEFINE 1 trial included roughly 3,400 adults with obesity or overweight, and roughly two-thirds of participants were women.

Earlier CagriSema findings from REDEFINE 1 focused on women and menopause classifications.

That analysis estimated average weight loss of 25% among women over 68 weeks, assuming participants remained on treatment. A previous analysis of women in REDEFINE 1 covered those results.